CanSinoBIO

CanSino Biologics Inc.

To provide innovative, high-quality and affordable vaccines

6185.HK
688185.SH



Overview

Founded in China in 2009, CanSino Biologics Inc. (CanSinoBIO) is an industry-leading biopharmaceutical company, dedicated to providing solutions for the prevention and treatment of infectious diseases globally, through research & development, manufacturing and commercialization of innovative high-quality and affordable vaccine products for human use. CanSinoBIO has been listed on the Main Board of Hong Kong Exchanges and Clearing Limited (HKEX: 6185.HK) and on the Sci-Tech Innovation Board of the Shanghai Stock Exchange (STAR Market, SSE: 688185), making it the first "A+H" dual-listed vaccine company in China.

Innovative Vaccine Portfolio

Vaccines for Major Emerging Infectious Diseases

Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Convidecia®
Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation Convidecia Air® and XBB.1.5 VARIANT
Recombinant Ebola Vaccine (Adenovirus Type 5 Vector) (Ad5-EBOV)

Meningitis Vaccine Combination

Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197) Menhycia® (3 months-6 years old)
Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197) Indication Expansion (7-59 years old)
Meningococcal group B Vaccine | Groups A and C Meningococcal Polysaccharide Conjugate Vaccine (CRM197) Menphecia®

Pneumococcal Vaccine Portfolio

13-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT) iPneucia®
Protein-based Pneumococcal Vaccine (PBPV) | 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT)

DPT Vaccine Combination

Adsorbed Diphtheria, Tetanus and Pertussis (acellular, three component) Combined Vaccine for Infants Tripecia®
Td5cp Adolescent and Adult | DT3cP-Hib-MCV4 Combined Vaccine

Other Vaccines

Inhaled Tuberculosis Vaccine (Adenovirus Type 5 Vector) | Recombinant Zoster Vaccine (Adenovirus Vector)
mRNA Multi-valent Influenza Vaccine | Absorbed Tetanus Vaccine
Recombinant Poliomyelitis Vaccine | Haemophilus Influenzae Type b Conjugate Vaccine, Freeze-dried
Other Combination Vaccine Candidates | Therapeutic Vaccine Candidates

Pipeline



*As of April, 2026

Company Milestones

2009

- Incorporated and registered in China

2015

- Pilot facility passed European QP inspection
- Obtained CTA approvals for MCV2 & MCV4

2017

- Obtained NDA approval for Ad-5-EBOV in China

2019

- Listed on the main board of HKEX

2020

- Listed on the Sci-Tech Innovation Board of SSE

2021

- The Recombinant Novel Coronavirus Vaccine Convidecia® received approval in over 10 countries
- Menphecia® and Menhycia® approved in China
- Received EU GMP Certificate

2022

- The WHO granted the Emergency Use Listing for the Recombinant Novel Coronavirus Vaccine Convidecia®
- The world's first inhaled Coronavirus vaccine Convidecia Air® approved as heterologous booster in China and Morocco
- The Shanghai R&D center & Phase I of the mRNA Manufacturing Facility completed

2023

- IM & IH of Zoster Vaccine approved for clinical trial in Canada
- Convidecia® obtained Halal Decree in Indonesia
- Initiated Phase Ib clinical trial for the global innovative vaccine PBPV
- Grant Agreement with the Gates Foundation for VLP-Polio

2024

- MCV4 received the drug registration certificate granted in Indonesia
- Obtained the Acceptance Notice of supplemental application to expand MCV4's applicable population to children aged from 3 months to 6 years old (83 months)
- VLP-Polio received further funding from the Gates Foundation, and initiated clinical trials in Australia (Phase I) and Indonesia (Phase I/II)
- Obtained the Acceptance Notice of drug registration applications for the PCV13*i*, DT3cP Infant
- Initiated Phase III clinical trial for the Absorbed Tetanus Vaccine
  Initiated Phase II /III clinical trial for the Td5cp Adolescent and Adult
  Initiated Phase I clinical trial for the Hib Vaccine
- Received positive results of Phase I clinical trials for the PBPV
- Collaborate with the National Institutes of Biotechnology Malaysia to develop the multivalent influenza mRNA vaccine

2025

- Menhycia® obtained Halal decree in Indonesia
- Signed agreement with business partner from Saudi Arabia to commercialize MCV4
- Application for registration of Absorbed Tetanus Vaccine
- Signed an exclusive commercialization agreement with Grand Life Science Group
- The DT3cP Infant vaccine obtained priority review by NMPA
- DT3cP-Hib-MCV4 combined vaccine approved for clinical trials
- Obtained approval for clinical trials of inhaled TB vaccine in Indonesia
- iPneucia® obtained NDA approval and officially launched

2026

- PCV24 received clinical trial approval
- MCV4 expanded age indication to include individuals up to age 6
- MCV4 and PCV13*i* manufacturing site received Malaysia NPRA PIC/S GMP Certificate
- DT3cP Infant vaccine Tripecia® obtained NDA approval
- Td5cp vaccine granted priority review by NMPA

Our Core Competencies

Five Key Technology Platforms

Adenovirus-based Viral Vector Technology

- Established mature viral vector packaging technology, high cell density production process and analytical characterization technology, enabling the rapid development of high-yield, quality-assured products using different cell substrates to meet various demands.

Protein Structure Design & VLP Assembly

- We have developed multiple antigen structure design technologies for predicting protein tertiary structure, distribution, immunogenicity and stability.
- Designed new recombinant strains to produce a next generation pertussis vaccines.
- The platform could be adapted for VLP vaccine design.

Synthetic Vaccine Technology

- Proprietary high-yield strain for production of CRM197.
- Various carrier protein options provide a foundation for the development of better multi-valent and combined vaccines.

mRNA Vaccine Technology

- Significant advantages include rapid production, scalable manufacturing and potentially lower cost.
- Established a universal development and manufacturing platform for mRNA technology, which shortens development duration and enables rapid commercial scale-up.

Formulation and Drug Delivery Technology

- We are committed to providing vaccines that are free of animal origins, and no phenol and preservatives included in the final products.
- Ensures consistent product quality and reduces potential side effects.

Innovative research and development

Over 17,000m² in R&D center, equipped with state-of-the-art laboratory resources

R&D Center

Published numerous high-impact papers in top-tier international journals, including *The Lancet and Nature.*

Established a leading R&D platform, equipped with comprehensive functions including early discovery, CMC development, clinical studies and registration.

- R&D function supported by a team of **approximately 270** specialists, **60%** of whom hold a PhD or Master's degree. The team comprises expertise in pathogen biology, structural biology, bioinformatics, immunology, AI-assisted antigen design and evaluation, registration and GMP production and testing. This diverse team enables support for the entire process.
- The company has extensive expertise in vaccine development, specializing in antigen discovery, CMC, and global clinical development. The company holds multiple core IP rights and proprietary technologies in vaccine and has published research articles in top-tier journals including *The Lancet and Nature*.

Possess core intellectual property rights for vaccines, domestic and international authorized invention patents, and proprietary technologies:

100+

"A Recombinant Novel Coronavirus Vaccine Using a Human Replication-Deficient Adenovirus as a Vector" was the first novel coronavirus vaccine patent in China.

Reliable Manufacturing

Fully Compliant with International Standards and Regulations, Including WHO, US, EU, China, and PIC/S

A state-of-the-art vaccine manufacturing facility, fully compliant with **WHO, USFDA, EU, NMPA, and PIC/S GMP** standards, leading domestically in capacity, automation, quality, and management.

Through digital transformation and Oracle's enterprise data bus, SAP, WMS, OMS, CRM, MES, LIMS, OA, eHR, and cost control systems are fully integrated, achieving end-to-end optimization from procurement to production and vaccine sales.

Strengthening environmental management, optimizing emissions and resource use, and driving green, low-carbon development.

Business layout

Established a professional marketing ecosystem on rapid access, wide coverage, and end market control

300+ Direct sales
Hybrid model of direct sales + sales agents
Academic promotion-oriented, deliver product value through CDC/KOLs/POVs.

Products portfolio **7**

- Menhycia®
- Tripecia®
- Menphecia®
- iPneucia®
- Convidecia®
- Convidecia Air®
- Recombinant Ebola Virus Disease Vaccine

Menhycia® and iPneucia® China Market Layout (as of the end of 2025)

Access to	CDC Access (prefectural level)	Covers
30 Provincial markets	1,500+	10,000+ POVs

In 2022, Menhycia® launched in China.
The combined sales of the Meningitis vaccine over 967 million RMB in 2025.

Our strategy: establish an innovative vaccine value chain

Supply based on target countries/regions' market demands ⇄ Strategic layout of talents and capital ⇄ International-standard technology transfer, supporting production localization ⇄ Clinical studies aligned with local research data and vaccination policy

To export innovative vaccines

Exported over 127 million doses of COVID-19 vaccines to countries along the Belt and Road Initiative.

- MCV4: reached partnership intention with relevant agencies in over 10 countries.
- PCV13*i*: with considerable overseas market potential.

Global market outlook

Actively advancing local registration and commercialization across Southeast Asia, the Middle East, North Africa(MENA), and South America.

CSR & ESG

Driven by a commitment to social value, CanSinoBIO supports public welfare and global health initiatives, collaborating with stakeholders to translate its corporate values into action and help build a healthier, more resilient society.



ESG Recognitions and Awards

S&P Global Sustainability Yearbook(China Edition) 2025/2026

2022-2025 ESG Ratings

ESG Ratings	2025	2024	2023	2022
MSCI	A	A	A	A
S&P CSA	44	42	39	37
HSI/HKQAA	BBB	BBB	BBB	BBB

Mission

To provide innovative, high-quality and affordable vaccines

Vision

Innovation for a safer world

Values

Respect, Agility, Innovation, Superior in quality, Engagement

Corporate Wechat: CanSinoBIO

Company Website: https://www.cansinotech.com.cn

Headquarter:
Biomedical Park, 185 South Avenue, TEDA West District, Tianjin, PRC
Tianjin:
No.139, Chengdu Road, Heping District, Tianjin
Beijing:
Floor 43, Fortune Financial Center, 5 Middle Dongsanhuan Road, Beijing
Shanghai:
C2, Phase 10 Lingang Intelligent Manufacturing Park, No.4188 Canghai Road, Fengxian District, Shanghai
1601, Building 1, Link Square Enterprise Plaza, No.222 Hubin Road, Huangpu District, Shanghai